Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
体外研究
Azeliragon (4 nM; 16 hours; T cells) treatment inhibits of wild type mice (WT) but not the deletion of the receptor (RAGE-/- mice) T cells and significant reduction in the production of IFN-γ.
Cell Viability Assay
Cell Line:
Purified T cells from RAGE-/- or WT B6 mice.
Concentration:
4 nM
Incubation Time:
16 hours
Result:
Inhibited of WT but not RAGE-/- T cells, and significantly reduced the level of IFN-γ.
体内研究
Azeliragon (100 mcg/d; intraperitoneal injection; every day) treatment reduces syngeneic islet graft and islet allograft in NOD and B6 mice (Islets were isolated from young prediabetic NOD/LtJ mice and transplanted into NOD mice with spontaneous diabetes; islets were isolated from WT BALB/c mice and transplanted into B6 mice with diabetes).
Animal Model:
Prediabetic NOD/LtJ (6-7 week old) mice, NOD mice with spontaneous diabetes, WT BALB/c mice (8-10 week old) and B6 mice with diabetes .
Dosage:
100 mcg/d
Administration:
Intraperitoneal injection; every day
Result:
Prolonged islet auto and allograft survival.
分子式
C32H38N3O2Cl
分子量
532.12
CAS号
603148-36-3
中文名称
阿齐瑞格
运输条件
Room temperature in continental US; may vary elsewhere.